Maze Therapeutics (NASDAQ:MAZE) CEO Sells $50,388.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 1,938 shares of the stock in a transaction on Friday, May 15th. The shares were sold at an average price of $26.00, for a total transaction of $50,388.00. Following the transaction, the chief executive officer directly owned 31,001 shares in the company, valued at approximately $806,026. The trade was a 5.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Stock Performance

MAZE opened at $25.03 on Thursday. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11. The company has a market cap of $1.39 billion, a price-to-earnings ratio of -9.89 and a beta of 2.50. Maze Therapeutics, Inc. has a 52-week low of $9.73 and a 52-week high of $53.65. The firm’s fifty day simple moving average is $32.19 and its two-hundred day simple moving average is $37.81.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The business had revenue of $20.00 million for the quarter. Equities analysts anticipate that Maze Therapeutics, Inc. will post -2.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Maze Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Royal Bank of Canada increased its position in Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Maze Therapeutics during the fourth quarter worth about $39,000. Caitong International Asset Management Co. Ltd acquired a new stake in Maze Therapeutics during the fourth quarter worth about $43,000. California State Teachers Retirement System increased its position in Maze Therapeutics by 138.0% during the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock worth $55,000 after purchasing an additional 766 shares during the last quarter. Finally, Ameritas Investment Partners Inc. increased its position in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares during the last quarter.

Analyst Ratings Changes

MAZE has been the topic of several research reports. BTIG Research reissued a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday, March 25th. Weiss Ratings reissued a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Guggenheim raised their price target on shares of Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Finally, JPMorgan Chase & Co. raised their price target on shares of Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 31st. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $66.00.

More Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Neutral Sentiment: HC Wainwright trimmed earnings estimates for Maze Therapeutics across multiple periods, including Q2 2026, Q3 2026, Q4 2026, full-year 2026, and longer-term years through 2030. While the firm kept a Buy rating and $110 price target, the lower EPS forecasts suggest analysts see a slower earnings path ahead.
• Negative Sentiment: Maze Therapeutics CEO Jason Coloma sold 1,938 shares in a pre-arranged Rule 10b5-1 plan. Even though the sale was planned and relatively small, insider selling can still weigh on investor sentiment, especially when paired with weaker analyst estimates.
• Negative Sentiment: The company recently reported quarterly EPS of ($0.45), missing expectations by a small margin. That earnings miss, combined with continued losses projected for the year, reinforces concerns that profitability may take time to materialize.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.